

DAFTAR PUSTAKA

- Abdar Esfahani M, Mokarian F, Karimipannah M. Alterations in the echocardiographic variables of the right ventricle in asymptomatic patients with breast cancer during anthracycline chemotherapy. *Postgraduate Medical Journal*. 2017 May 1;93(1099):271–4
- Amstrong GT, Oeffinger KC, Chen Y, Kawashima T, et al. Modifiable Risk Factors and Major Cardiac Event among Adult Survivors of Childhood Cancer. *J Clin Oncol* 2013;31:3673-3680
- Andersson A, Naslund U, Tavelin B et al. Long-term risk of cardiovascular disease in Hodgkin lymphoma survivors--retrospective cohort analyses and a concept for prospective intervention. *Int J Cancer*. 2009;124(8):1914-1917
- Arena R, Cahalin LP, Borghi-Silva A, Phillips SA. Improving functional capacity in heart failure: the need for multifaceted approach. *Curr Opin Cardiol*. 2014; 29(5):467-74
- Barendswaard EC, Prpic H, Van der Wall EE, Camps JA, Keizer HJ, Pauwels EK. Right ventricle wall motion abnormalities in patients treated with chemotherapy. *Clinical nuclear medicine*. 1991 Jul 1;16(7):513-6
- Baysan O, Ocakli EP, Saglam Y et al. Advances in echocardiography:global longitudinal strain, intra-cardiac multidirectional flow imaging and automated 3d volume analysis. *Heart Vessels and Transplantation*. 2018;2
- Belham M, Kruger A, Pritchard C. The Tei index identifies a differential effect on left and right ventricular function with low-dose anthracycline chemotherapy. *Journal of the American Society of Echocardiography*. 2006 Feb 1;19(2):206-10
- Boczar KE, Aseyev O, Sulpher J, et al. Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy. *Echo Res Pract*. 2016;3:79–84

- Calleja A, Poulin F, Khorolsky C, et al. Right ventricular dysfunction in patients experiencing cardiotoxicity during breast cancer therapy *J Oncol*. 2015;2015:609194
- Cardinale D, Colombo A, Torisi R et al. Trastuzumab-induced Cardiotoxicity: Clinical and Prognostic Implication of Troponin I Evaluation. *J Clin Oncol*. 2010;28:3910-3916
- Cardinale D, Sandri MT. Role of biomarker in chemotherapy induced cardiotoxicity. *Prog Cardiovasc Dis*. 2010;53:121-129
- Chow EJ, Chen W, Kremer LC et al. Individual prediction of heart failure among childhood cancer survivors. *J Clin Oncol*. 2015;33:394-402
- Corremans R, Adao R, De Keulenaer GW et al. Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. *Clin Exp Pharmacol Physiol*. 2019;46:204-215
- Cottin Y, Touzery C, Coudert B, Richebourg S, Cohen M, Toubreau M, Louis P, Wolf JE, Brunotte F. Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline?. *European journal of nuclear medicine*. 1996 May;23(5):511-6
- De Azambuja E, Procter MJ, van Veldhuisen DJ et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1-01). *J Clin Oncol*. 2014;32(20):2159-65
- Dhesi S, Chu MP, Blevins G et al. Cyclophosphamide-induced cardiomyopathy: a case report, review, and recommendations for management. *J. Investig. Med. High Impact Case Rep*. 2013:1-7
- Esfahani MA, Mokarian F, Karimipناه M. Alterations in the echocardiographic variables of the right ventricle in asymptomatic patients with breast cancer during anthracycline chemotherapy. *Postgraduate medical journal*. 2017 May 1;93(1099):271-4
- Ewer MS, Littman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. *Journal of Clinical Oncology*. 2006;23(13):2900-2902

- Farag EM, Al-Daydamony MM, Gad MM. What is the association between left ventricular diastolic dysfunction and 6-minute walk test in hypertensive patients?. *J Am Hypertens*. 2017;11(3):158-164
- Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, et al. Cancer Incidence and Mortality Patterns in Europe: Estimates for 40 Countries in 2012. *Eur J Cancer* 2013;49:1374-1403
- Frey MK, Bergler-Klein J. Echocardiographic evaluation of patients undergoing cancer therapy. *European Heart Journal – Cardiovascular Imaging*. 2021;22:375-382
- Geisber CA, Sawyer DB. Mechanism of anthracycline cardiotoxicity and strategies to decrease cardiac damage. *Curr Hypertens Rep*. 2010;12:404-410
- Global Cancer Observatory GLOBOCAN 2020. <http://gco.iarc.fr/> (accessed at 18/3/2021. 10.57 WITA)
- Gordon LI, Burke MA, Singh AT et al. Blockade of the Erb B2 receptor induced cardiomyocytes death through mitochondrial and reactive oxygen species-dependent pathway. *J Biol Chem*. 2009;284:2080-7
- Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, part I: anatomy, physiology, aging, and functional assessment of the right ventricle. *Circulation*. 2008 Mar 18;117(11):1436-48
- Hamo CE, Bloom MW. Cancer and heart failure: Understanding the intersection. *Cardiac Failure Review* 2017;3(1):66-70
- Jiang Z, Zhou M. Neurgulin signaling and heart failure. *Curr Heart Fail Rep*. 2010;7:42-7
- Ky B, Putt M, Sawaya H, Freanch B, et al. Ealy Increase in multiple biomarker predict subsequent cardiotoxicity in patient with breast cancer treated with doxorubicin, taxane, and trastuzumab. *J Am Coll Cardiol*. 2014;63:809-816
- Kilicaslan B, Ozdogan O, Demir Piskin G, Kahya Eren N, Dursun H. Echocardiographic signs of right ventricle changes after Trastuzumab treatment in breast cancer

- patients with erb-2 overexpression. *Anadolu Kardiyol Derg.* 2015 Feb 12;15(2):143–8.
- Kemenkes, RI. 2019. 'Info DATIN (Pusat Data Dan Informasi Kementerian Kesehatan RI)', Kementerian Kesehatan Republik Indonesia.
- Lang RM, Badano LP, Mor-Avi V et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging.* 2015;16:233-70
- Laporan Nasional Riskesdas 2018 (RISKESDAS 2018)/ Badan Penelitian dan Pengembangan Kesehatan. Jakarta: Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan, 2019
- Lenneman CG, Sawyer DB. Cardio-oncology. An update on cardiotoxicity of cancer-related treatment. *Circ Res.*2016;118:1008-1020
- Link W. Cancer treatment. In principles of cancer treatment and anticancer drug development. 2019. Springer. Cham: 7-76
- Linschoten M, Teske AJ, Cramer MJ et al. Chemotherapy-related cardiac dysfunction. A systematic review of genetic variants modulating individual risk. *Gir Genom Precis Med.* 2018;11(e001753):1-12
- Montani D., Bergot E., Gunther S., Savale L., Bergeron A., Bourdin A. et al., Pulmonary arterial hypertension in patients treated by dasatinib, *Circulation* 125 (2012) 2128–2137
- Muszalik M, Dijkstra A, Kedziora-Kornatowska K, Zielinska-Wieczkowska H et al. Independence of elderly patients with arterial hypertension in fulfilling their needs, in the aspect of functional assesment and quality of life (QoL). *Arch Gerontol Geriatr.* 2011;52(3):e204-9
- Negro A, Brar BK, Gu Y, Petersin KL et al. Erb B2 is required for G-protein coupled receptor signaling in the heart. *Proc Natl Acad Sci U S A;*2006(103):15889-93
- Nitiss KC, Nitiss JL. Twisting and ironing: doxorubicin cardiotoxicity by mitochondrial DNA damage. *Clin Cancer Res.* 2014;20(18):4737-9

- Nowsheen S, Viscuse PV, O'Sullivan CC et al. Incidence, Diagnosis, and Treatment of Cardiac Toxicity from Trastuzumab in Patients with Breast Cancer. *Curr Breast Cancer Rep.* 2017;9(3):173-182
- Perez IE, Alam ST, Hernandez GA, Sancassani R. Cancer therapy-related cardiac dysfunction: an overview for the clinician. *Clinical Medicine Insights: Cardiology.* 2019 (13):1-11
- Plana JC, Galderisi M, Barac A, Ewer MS et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the american society of echocardiography and the european association of cardiovascular imaging. *European Heart Journal – Cardiovascular Imaging* 2014; 15:1063-1093
- Planek MIC, Manshad A, Hein K, Hemu M, Ballout F, Varandani R, et al. Prediction of doxorubicin cardiotoxicity by early detection of subclinical right ventricular dysfunction. *Cardio-Oncology.* 2020 Dec;6(1):10.
- Rudski L.G., Lai W.W., Afilalo J., Hua L., Handschumacher M.D., Chandrasekaran K. et al., Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography, *J Am Soc Echocardiogr* 23 (2010) 685–713. quiz 786–8
- Sawyer DB, Peng X, Chen B et al. Mechanisms of Anthracycline Cardiac Injury: Can We Identify Strategies for Cardioprotection?. *Progress in Cardiovascular Disease.* 2010;53:105-113
- Shakir DK, Rasul KI. Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management. *J Clin Med Res.* 2009;1(1):8-12
- Shi X, Wang Y, Zhou J. Mechanical property evaluation of the right ventricular myocardium in cancer patients with chemotherapy by echocardiography: a systematic review and meta-analysis. *Transl Cancer Res TCR.* 2022 May;11(5):1122–40

- Suster TM, Ewer MS. Cancer drug and heart: important and management. *Eur Heart J*. 2013;34;1102-1111
- Tadic M, Cuspidi C, Hering D, Venneri L, Danylenko O. The influence of chemotherapy on the right ventricle: did we forget something?. *Clinical cardiology*. 2017 Jul;40(7):437-43
- Tadic M, Baudisch A, Haßfeld S, Heinzl F, Cuspidi C, Burkhardt F, et al. Right ventricular function and mechanics in chemotherapy- and radiotherapy-naïve cancer patients. *Int J Cardiovasc Imaging*. 2018 Oct;34(10):1581–7.
- Tanindi A., Demirci U., Tacoy G., Buyukberber S., Alsancak Y., Coskun U. et al., Assessment of right ventricular functions during cancer chemotherapy, *Eur J Echocardiogr* 12 (2011) 834–840
- Thavendiranathan P, Wintersperger BJ, Flamm SD, Marwick TH. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. *Circ Cardiovasc Imaging*. 2013;6:1080-1091
- Voight JU, Cvijic M. 2- and 3- dimensional myocardial strain in cardiac health and disease. *JACC CardiovascImaging*. 2019;12(9):1849-63
- Wei-Ting Chang, Wei-Ting Chang, Jih-Yuan Shih, Yin-Hsun Feng, Chun-Yen Chiang, Yu Hsuan Kuo, et al. The Early Predictive Value of Right Ventricular Strain in Epirubicin-Induced Cardiotoxicity in Patients with Breast Cancer. *Acta Cardiologica Sinica*. 2016 Sep 30;32(5)
- WHO. Cancer. <https://www.who.int/news-room/fact-sheets/detail/cancer> (accessed at 19/3/2021. 10.16 WITA)
- Zamorano JL, Lancellotti P, Munoz DR. 2016 position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines. *European Heart Journal*. 2016;37:2768-2801

Lampiran 1



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari., MMed.PhD. SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 502/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 13 September 2022


Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22070358	No Sponsor	Protokol
Peneliti Utama	dr. Bambang Gunawan	Sponsor	
Judul Peneliti	PERUBAHAN FUNGSI VENTRIKEL KANAN PADA PASIEN KANKER YANG MENJALANI KEMOTERAPI		
No Versi Protokol	2	Tanggal Versi	5 September 2022
No Versi PSP	2	Tanggal Versi	5 September 2022
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input checked="" type="checkbox"/> Fullboard Tanggal 3 Agustus 2022	Masa Berlaku 13 September 2022 sampai 13 September 2023	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2

**KEMENTERIAN KESEHATAN REPUBLIK INDONESIA****DIREKTORAT JENDERAL PELAYANAN KESEHATAN**

RUMAH SAKIT UMUM PUSAT DR. WAHIDIN SUDIROHUSODO

Jalan Perintis Kemerdekaan Km. 11 Tamalanrea, Makassar, Kode Pos 90245

Telp. (0411) 584675 – 581818 (*Hunting*), Fax. (0411) 587676Laman : www.rsupwahidin.com Surat Elektronik : tu@rsupwahidin.com

Nomor : DP.04.03/D.XIX.2/4897/2023
Hal : Izin Penelitian

24 Maret 2023

**Yth. KPS. Jantung dan Pembuluh Darah
Fakultas Kedokteran Universitas Hasanuddin**

Sehubungan dengan surat saudara nomor **5347/UN4.6.8/PT.01.04/2023**, tertanggal **24 Februari 2023**, hal **Permohonan Izin Penelitian**, dapat kami fasilitasi dan memberikan izin pelaksanaan penelitian kepada:

Nama : **dr. Bambang Gunawan**
NIM : **C165 182 002**
Prog. Pend. : **MPPDS Kardiologi dan Pembuluh Darah**
No. HP : **085362642226**
Judul : **Perubahan Fungsi Ventrikel Kanan Pada Pasien Kanker Yang Menjalani Kemoterapi**
Jangka Waktu : **Tiga Bulan Setelah Surat ini di Keluarkan**
Lokasi : **Inst. Pusat Jantung Terpadu**

dengan ketentuan sebagai berikut :

1. Sesuai dengan peraturan dan ketentuan penelitian yang berlaku di lingkup RSUP Dr Wahidin Sudirohusodo
2. Sebelum meneliti, peneliti wajib melapor kepada Pengawas Penelitian di masing-masing unit yang menjadi lokasi penelitian
3. Pelaksanaan penelitian tidak mengganggu proses pelayanan terhadap pasien
4. Pemeriksaan penunjang, BHP dan lain-lain yang digunakan dalam penelitian, menjadi tanggung jawab peneliti, tidak dibebankan kepada pasien ataupun RS
5. Peneliti melaporkan proses penelitian secara periodik serta hasil penelitian di akhir waktu penelitian
6. Mencantumkan nama RSUP Dr Wahidin Sudirohusodo sebagai afiliasi institusi dalam naskah dan publikasi penelitian
7. Surat Keterangan Selesai Penelitian menjadi salah satu syarat untuk mengikuti Seminar Hasil Penelitian
8. Bukti Penyerahan Skripsi/Thesis/Disertasi ke RSUP Dr Wahidin Sudirohusodo menjadi syarat penyelesaian studi.

Mohon dapat dipastikan agar ketentuan tersebut dipenuhi peneliti sebelum menyelesaikan studi di institusi saudara. Atas perhatian dan Kerjasama yang baik, diucapkan terima kasih.

a.n. Direktur Utama
Plt. Direktur Sumber Daya Manusia,
Pendidikan dan Penelitian,



Ridhayani B, SKM, M.Kes
NIP197110271997032001

Tembusan:

1. Kepala Instalasi Pusat Jantung Terpadu (Cardiac Centre)

Lampiran 3

No	Nama	RM	Tgl lahir	Umur	Jenis Kelamin	BB	TB	DMI	HT	Merokok	Diagnosa	EF	Tgl Pre	Tgl Post	TAPSE PRE
1	St Asyika (RSUH)	996187	02/07/1979	43	P	61	169	-	-	-	Ca Mammae Dextra	58%	14/10/2022	01/12/2022	2.1
2	Harsun Idjin (RSUH)	994666	02/03/1972	51	L	46	153	-	+	-	Limfoma Maligna Hodgkin	62%	02/12/2022	05/01/2023	2.2
3	Naimang (RSUH)	993589	02/04/1963	59	P	52	155	-	+	-	Ca Mammae Dextra	58%	19/09/2022	05/12/2022	2.3
4	Kartiah (RSUH)	991792	09/01/1981	42	P	60	152	-	-	-	Ca Mammae Dextra	61%	18/10/2022	07/12/2022	1.7
5	Jami (RSUH)	990993	29/11/1967	55	P	45	155	-	+	-	Ca Mammae Dextra	59%	13/10/2022	08/12/2022	2.0
6	Erni Yanti (RSUH)	996677	03/05/1982	40	P	59	154	-	-	-	Ca Mammae	66%	19/10/2022	30/01/2022	2.2
7	Karyawati (RSUH)	1001895	25/09/1988	34	P	74	163	-	-	-	Ca Mammae	61%	06/12/2022	26/01/2022	2.1
8	Fatmawati	813399	12/05/1967	55	P	41	146	-	-	-	Ca Mammae	62%	10/10/2022	13/01/2022	2.1
9	Fatmawati (RSUH)	988692	07/04/1972	50	P	61	160	-	-	-	Ca Mammae	64%	01/08/2022	14/10/2022	2.0
10	Delima (RSUH)	990367	30/11/1994	28	P	48	150	-	-	-	Ca Mammae	63%	18/08/2022	10/12/2022	2.0
11	St Amibah (RSUH)	991123	12/04/1965	57	P	53	165	-	-	-	Ca Mammae	63%	25/08/2022	17/10/2022	2.1
12	Margaretha Paembonan (RSUH)	991885	04/03/1960	63	P	49	155	+	-	-	Ca Mammae sinistra	64%	02/09/2022	30/11/2022	1.9
13	Martina (RSUH)	608273	14/05/1963	59	P	50	155	-	-	-	Ca Mammae	67%	28/10/2022	12/12/2022	2.3
14	Kartini (RSUH)	995470	21/04/1967	55	P	55	160	-	-	-	Ca Mammae	68%	07/10/2022	25/11/2022	2.5
15	Hairani (RSUH)	988579	20/10/1990	32	P	58	155	-	-	-	Ca Mammae sinistra	66%	01/09/2022	10/11/2022	2.0
16	Syarana (RSUH)	991689	02/05/1975	47	P	48	151	-	-	-	Ca Mammae Dextra	65%	19/10/2022	30/11/2022	2.0
17	Putri Bone (RSUH)	998020	19/03/1972	50	P	45	150	-	-	-	Ca Mammae Dextra	62%	31/10/2022	03/02/2023	1.9
18	Nurhaedah (RSUH)	999246	27/07/1961	61	P	55	157	-	+	-	Ca Mammae sinistra	67%	10/11/2022	13/02/2023	1.9
19	Nurhayati (RSUH)	993227	02/07/1980	42	P	75	165	-	-	-	Limfoma Maligna Hodgkin	61%	24/10/2022	13/02/2023	2.2
20	Badriyatul M.	1000898	23/12/2001	21	P	52	153	-	-	-	Sarcoma axilla sinistra	65%	26/12/2022	13/02/2023	1.8
21	Irmawati (RSUH)	1002242	29/08/1976	46	P	64	156	+	-	-	Ca Mammae sinistra	67%	09/12/2022	13/02/2023	2.1
22	Akwila Wabiser	992896	30/04/1965	57	L	56	170	-	-	-	Ca Mammae sinistra	56%	14/09/2022	14/02/2023	2.1
23	Aminah	988909	23/09/1957	65	P	69	160	-	-	-	Ca Mammae dextra	61%	08/08/2022	16/02/2023	2.1
24	Yusni (RSUH)	716708	31/12/1952	70	P	47	148	-	-	-	Ca Mammae dextra	65%	10/10/2022	15/02/2023	2.0
25	Mitha Rosiana (RSUH)	1001163	04/05/1984	38	P	55	158	-	-	-	Ca Mammae sinistra	67%	28/11/2022	24/02/2023	2.1
26	Nuha Agustiani (RSUH)	992956	06/09/1979	43	P	55	158	-	-	-	Limfoma Maligna Non Hodgkin	65%	13/09/2022	14/03/2023	2.0
27	A. Ramlah Budy (RSUH)	985434	06/07/1968	54	P	65	155	-	-	-	Ca Mammae sinistra	69%	07/09/2022	07/03/2023	2.0
28	Rahmawati (RSUH)	1008149	17/07/1967	55	P	68	158	-	-	-	Ca Mammae sinistra	68%	02/02/2023	02/03/2023	2.0
29	Evit Hanning (RSUH)	1005650	25/04/1976	46	P	52	152	-	-	-	Ca Mammae sinistra	70%	12/01/2023	03/03/2023	2.2
30	Wahida (RSUH)	1009661	14/02/1966	56	P	56	149	-	-	-	Ca Mammae	66%	14/12/2022	14/02/2023	1.9
31	Berna Deta Ganur	992484	14/10/1978	44	P	51	165	-	-	-	Ca Mammae sinistra	64%	08/09/2022	09/12/2022	2.2
32	Erni Karim	988318	18/12/1979	43	P	60	150	-	-	-	Ca Mammae Dextra	63%	25/10/2022	12/12/2022	2.5
33	Fitrawati (RSUH)	991909	27/07/1977	45	P	53	157	-	-	-	Ca Mammae	64%	02/09/2022	18/10/2022	2.3
34	Nurhasnah Rahmin (RSUH)	994547	1972-03-07	51	P	48	146	-	-	-	Ca Mammae	63%	28/09/2022	04/11/2022	1.9
35	Sitti Nursia Pilo	975206	25/08/1962	60	P	61	145	-	-	-	Ca Mammae	60%	28/09/2022	07/11/2022	1.9
36	Wa Ode Hatima	989524	01/07/1975	47	P	61	151	-	-	-	Ca Mammae Dextra	63%	09/08/2022	30/09/2022	2.1
37	Andi Farida	997633/1007302	25/08/1959	63	P	50	147	+	-	-	Ca Mammae	69%	27/10/2022	26/01/2023	2.2
38	Darmayana	1003076	03/10/1978	44	P	55	155	-	-	-	Ca Mammae Dextra	64%	30/12/2022	25/01/2023	2.3
39	A. Manganty	1008769	10/09/1971	51	P	70	155	-	-	-	Ca Mammae Dextra	61%	20/11/2022	07/02/2023	2.2

Lampiran 3

TAPSE POST	S' PRE	S' POST	FAC PRE	FAC POST	Regimen	
1,8	14	10	47	46	Fonkopac (Cisplatin) 330mg + Epirubicin 80mg	5
1,8	12	10	46	43	doxorubicin + cysplatin + bleomisin + dacarbazine	5
2,0	18	13	50	48	Brexel + Doxorubicin + Cyclophosphamide	3
1,7	10	10	45	44	Doxorubicin 70mg + Paclitaxel 260mg	1
1,8	13	11	46	42	Paclitaxel + Epirubicin + Cyclophosphamide	3
1,9	12	11	45	40	Paclitaxel + Epirubicin + Cyclophosphamide	3
2,0	14	11	50	49	doxorubicin 100mg + Cyclophosphamide 1000mg + Docetaxel 180mg	3
1,8	12	11	50	46	docetaxel 100 milligram per intravena, epirubicin 75 milligram per intravena	1
1,9	12	10	50	44	Paclitaxel + Epirubicin + Cyclophosphamide	3
1,8	11	10	47	43	Doxorubicin + Paclitaxel	1
1,8	14	10	46	44	Paclitaxel 280mg + Epirubicin 80mg + Cyclophosphamide 800mg	3
1,7	11	10	44	42	Brexel (Docetaxel) + Epirubicin + Cyclophosphamide	3
2,0	13	11	48	41	Brexel + Doxorubicin + Cyclophosphamide	3
2,0	14	11	47	44	Brexel + Doxorubicin + Cyclophosphamide	3
1,8	11	10	47	42	Brexel (Docetaxel) + Epirubicin + Cyclophosphamide	3
1,7	13	10	47	44	Paclitaxel + Epirubicin + Cyclophosphamide	3
1,8	12	10	45	39	Paclitaxel + Epirubicin + Cyclophosphamide	3
1,7	12	10	48	43	Brexel 110mg + Epirubicin 70mg + Cyclophosphamide 700mg	3
1,8	15	13	45	42	doxorubicin + cysplatin + bleomisin + dacarbazine	5
1,7	14	12	45	45	Dacarbasin 1800mg, doxorubicin 75mg	2
1,8	17	14	44	41	Brexel 120mg + Doxorubicin 80mg + Cyclophosphamide 800mg	3
1,7	17	13	49	45	Doxorubicin + Cyclophosphamide 407.5mg + Fludarabin 40.75mg	4
1,8	11	10	44	42	docetaxel 835 milligram per intravena, epirubicin 83.5 milligram per intravena, 5-fu 835 milligram per intravena	4
1,8	16	14	45	42	Paclitaxel + Epirubicin + Cyclophosphamide	3
1,8	14	10	50	44	Doxorubicin 90mg + Cyclophosphamide 900mg	2
1,7	13	10	45	38	Cyclophosphamide + doxorubicin + vinkristin + Mabthera	5
1,8	11	10	50	48	Brexel (Docetaxel) + Epirubicin + Cyclophosphamide	3
1,8	13	10	44	41	Paclitaxel + Epirubicin + Cyclophosphamide	3
1,8	16	13	46	44	Brexel (Docetaxel) + Epirubicin + Cyclophosphamide	3
1,7	12	10	48	46	Paclitaxel 260mg, Epirubicin 70mg, Cyclophosphamide 700mg	3
1,8	14	11	47	44	Paclitaxel + Epirubicin + Cyclophosphamide	3
2,0	15	11	45	41	Brexel (Docetaxel) + Epirubicin + Cyclophosphamide	3
1,8	14	11	45	43	Paclitaxel 270mg + Epirubicin 90mg	2
1,7	14	10	49	45	Brexel (Docetaxel) + Epirubicin + Cyclophosphamide	3
1,7	11	10	46	40	Brexel (Docetaxel) + Epirubicin + Cyclophosphamide	3
1,7	13	10	43	37	Paclitaxel + Epirubicin	2
1,9	13	10	47	45	Paclitaxel + Epirubicin + Cyclophosphamide	3
1,9	14	12	46	43	Paclitaxel + Epirubicin + Cyclophosphamide	3
1,9	17	14	48	45	Brexel 130mg, Epirubicin 80mg	2